Lumbrokinase
Lumbrokinase is a complex of six fibrinolytic enzymes extracted from earthworms (mainly Lumbricus rubellus), used for decades in Chinese clinical medicine for stroke recovery and thromboembolism. It dissolves fibrin directly and also activates plasminogen — the body's own clot-dissolving system. In North America and Europe it's sold as a dietary supplement, not a drug, with no quality oversight. The strongest published trials are from China and Indonesia and tested lumbrokinase ON TOP of standard antiplatelet or anticoagulant therapy, not as a replacement. The dominant safety issue is bleeding risk, especially in combination with anticoagulants, antiplatelets, or near surgery.
Quick decision guide
May help most
There is no clearly established self-supplement use case in healthy adults. Some integrative-cardiology clinicians use it under supervision for hypercoagulable states, post-stroke recovery, or as an adjunct in patients who don't tolerate standard antiplatelet therapy — always with active monitoring of bleeding and clotting parameters.
Common dosing range
Most clinical trials use 600,000–1,200,000 IU (~20–40 mg standardized lumbrokinase) twice daily on an empty stomach. Dietary supplement products vary wildly in actual enzyme activity. Use ONLY under clinician supervision.
When to expect effects
Days to weeks for changes in fibrinogen and clotting markers; longer for clinical endpoints.
Watch out for
BLEEDING RISK is the dominant concern. Do not combine with warfarin, DOACs (apixaban, rivaroxaban, dabigatran, edoxaban), heparin, aspirin, clopidogrel, or NSAIDs without clinician supervision. Stop at least 1–2 weeks before any planned surgery, dental work, or invasive procedure. Avoid in active bleeding, recent stroke, peptic ulcer disease, severe liver disease, or any bleeding diathesis.
Evidence snapshot
What is it
Lumbrokinase is a complex of fibrinolytic enzymes extracted from earthworms (Lumbricus rubellus). It is used in supplements for cardiovascular and circulatory support, with claims about clot dissolution and platelet effects.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
Ischemic stroke recovery (adjunct to standard care) Limited Evidence | Better functional recovery scores at 28 days vs aspirin alone in one published RCT | Post-acute ischemic stroke patients under specialist care who could safely add an adjunct | Weeks (functional recovery measured at 28 days in the cited trial) |
Cardiovascular / thromboembolic disease (general) Mixed Evidence | Reductions in fibrinogen and blood viscosity; clinical-endpoint data limited | Patients in integrative-cardiology care for hypercoagulable states or supplement-sensitive adjunct decisions | Weeks for biomarker changes; clinical outcomes not well characterized in Western trials |
Chronic infection / 'biofilm' integrative use (Lyme, persistent infections) Mixed Evidence | No controlled-trial efficacy data for this use | Patients in specialized integrative care where clinician and patient understand the evidence is hypothetical | Not established |
Ischemic stroke recovery (adjunct to standard care)
- Effect
- Better functional recovery scores at 28 days vs aspirin alone in one published RCT
- Best fit
- Post-acute ischemic stroke patients under specialist care who could safely add an adjunct
- Time
- Weeks (functional recovery measured at 28 days in the cited trial)
Cardiovascular / thromboembolic disease (general)
- Effect
- Reductions in fibrinogen and blood viscosity; clinical-endpoint data limited
- Best fit
- Patients in integrative-cardiology care for hypercoagulable states or supplement-sensitive adjunct decisions
- Time
- Weeks for biomarker changes; clinical outcomes not well characterized in Western trials
Chronic infection / 'biofilm' integrative use (Lyme, persistent infections)
- Effect
- No controlled-trial efficacy data for this use
- Best fit
- Patients in specialized integrative care where clinician and patient understand the evidence is hypothetical
- Time
- Not established
Evidence for 3 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
Ischemic stroke recovery (adjunct to standard care)
Disease adjunctCao 2013 randomized 310 ischemic-stroke patients to lumbrokinase plus aspirin vs aspirin alone for 28 days; the lumbrokinase arm showed better Barthel Index and NIH stroke scale recovery scores, without a significant increase in symptomatic intracranial hemorrhage. Other Chinese-language trials report similar adjunctive benefit on functional outcomes and fibrinogen levels. Note: lumbrokinase was always tested ON TOP of antiplatelet therapy, never as a substitute. Methodology and publication quality of trials vary widely.
Bottom line: Promising adjunct signal in stroke recovery, but evidence quality is uneven and use should be specialist-supervised. Never substitute for standard antiplatelet/anticoagulant therapy.
Evidence is mixed
Most positive trials are from Chinese-language journals with methodology limitations; replicated high-quality Western RCTs are absent. Effect sizes vary. Trial duration is short relative to long-term stroke outcomes.
Cardiovascular / thromboembolic disease (general)
Disease adjunctLumbrokinase has been studied in coronary heart disease, hyperviscosity syndromes, deep vein thrombosis, and after coronary stenting in mostly small Asian trials. Mechanism (direct fibrinolysis plus plasminogen activation plus mild antiplatelet effect) is plausible and reduces fibrinogen and whole-blood viscosity in human studies. Clinical outcome data outside stroke is sparse and uncontrolled; quality of available trials is limited. North American and European cardiology guidelines do not recommend lumbrokinase.
Bottom line: Real mechanism, weak clinical-outcome evidence outside stroke trials. Not a substitute for guideline-directed cardiology care.
Chronic infection / 'biofilm' integrative use (Lyme, persistent infections)
Mechanism onlyIn integrative-medicine practice (especially around chronic Lyme and persistent tick-borne co-infections), lumbrokinase and similar enzymes (nattokinase, serrapeptase) are used on the rationale that fibrinolytic activity may disrupt bacterial biofilms or microclots. The mechanism is hypothesized rather than demonstrated in human clinical trials; there are no published controlled trials of lumbrokinase for Lyme or chronic infectious disease. Bleeding risk applies the same as in any other use.
Bottom line: An unproven use even within integrative practice; the bleeding risk is real even when the benefit is hypothetical.
How it works
How to take it
What to track
Bottom line: This is not a casual supplement. Use ONLY under specialist supervision, with active bleeding-risk monitoring, on an empty stomach, and never together with anticoagulants/antiplatelets without explicit coordination. Stop two weeks before any procedure.
4 commercial forms
Compare the main delivery options and what they’re best suited for.
Lumbrokinase enteric capsule (dietary supplement)
Most common consumer formLumbricus rubellus extract in delayed-release enteric capsule. Enteric coating protects the protease from gastric acid. Look for stated enzyme units (IU or FU) per capsule and third-party verification.
Quality and labeled potency vary widely; verify with third-party testing.
DLBS1033 (Indonesian pharmaceutical form)
Standardized drugA pharmaceutical-grade standardized Lumbricus rubellus extract registered as a drug in Indonesia. Used in cardiology trials there. Not generally available as such in the US/EU.
Pharmaceutical standardization; reference product in some trials.
Nattokinase
Related but distinctA fibrinolytic enzyme from fermented soy (natto), not earthworm-derived. Different enzyme, similar broad mechanism (fibrinolysis), similar bleeding-risk profile. Distinct product with its own evidence base — see the Nattokinase page (if available).
Different source organism; do not stack with lumbrokinase.
Serrapeptase
Related but distinctA proteolytic enzyme from Serratia bacteria, used for inflammation and mucus thinning. Different enzyme class (serine protease, not direct fibrin-cleaving) but often marketed adjacent to lumbrokinase. Not interchangeable.
Different mechanism; different evidence base.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Serious bleeding events including gastrointestinal bleeding, hematuria, intracranial hemorrhage. Risk is sharply higher in combination with anticoagulants (warfarin, DOACs, heparin), antiplatelets (aspirin, clopidogrel, prasugrel, ticagrelor), NSAIDs, or SSRIs. Most documented bleeding events occur in this combination context.
Perioperative bleeding if not stopped in advance. Must be discontinued at least 1–2 weeks before any surgery, dental extraction, colonoscopy, biopsy, or other invasive procedure to allow normal hemostasis to recover.
Hypersensitivity / allergic reactions, including (rarely) anaphylaxis. The product is a foreign protein complex from earthworm tissue; people with multiple environmental allergies or asthma are at theoretically higher risk.
Quality and dose accuracy of dietary supplement products is poor. Labels often state 'units' that don't reflect actual fibrinolytic activity, and contamination with heavy metals or microbial load has been documented in unregulated products.
Who should avoid it
- Anyone taking warfarin, DOACs (apixaban, rivaroxaban, dabigatran, edoxaban), heparin, aspirin (including low-dose 81 mg), clopidogrel, prasugrel, ticagrelor, or chronic NSAIDs/SSRIs without explicit clinician coordination.
- Anyone with active bleeding, recent hemorrhagic stroke, peptic ulcer disease, severe liver disease, severe thrombocytopenia, hemophilia, or any bleeding diathesis.
- Anyone with surgery, dental procedure, colonoscopy, biopsy, or any invasive procedure planned within the next 2 weeks.
- Pregnant or breastfeeding people — safety not established.
- People with documented allergies to earthworm protein or multiple severe environmental allergies.
- Children — not studied; safety not established.
Pregnancy & breastfeeding
Avoid in pregnancy and breastfeeding. Safety data are insufficient and the bleeding-risk profile alone would warrant avoidance. There is no clinical scenario in which the benefit-risk equation supports use in pregnancy.
Bottom line: Bleeding is the headline risk. Even healthy adults using lumbrokinase alone should be aware of the easy-bruising potential; combinations with anticoagulants or antiplatelets are clinically meaningful and should only happen under specialist supervision.
Interactions
Additive bleeding risk through different mechanisms (warfarin inhibits vitamin-K-dependent clotting; lumbrokinase directly lyses fibrin and activates plasminogen). Combination should generally be avoided; if specifically needed, requires close INR and bleeding-symptom monitoring.
Additive bleeding risk via independent pathways. There is no monitoring assay to titrate the combined effect. Combination should generally be avoided.
Additive bleeding risk. Lumbrokinase use during hospitalization on heparin therapy is contraindicated.
Most positive lumbrokinase trials in stroke specifically tested it on top of aspirin without a significant excess bleeding signal, but clinical practice still requires bleeding-symptom monitoring and dose awareness. Dual antiplatelet therapy + lumbrokinase compounds risk further.
NSAIDs impair platelet function and irritate the GI mucosa, both compounded by lumbrokinase's fibrinolytic activity. Avoid the combination when possible.
SSRIs reduce platelet serotonin release and modestly increase bleeding risk on their own; combination with fibrinolytic enzymes compounds the effect.
Cumulative bleeding effect when stacking multiple agents with antiplatelet or fibrinolytic activity. Use one at a time, not as a stack.
Food sources
| Food | Amount | %DV |
|---|---|---|
| Not a dietary nutrient — supplement / pharmaceutical only | N/A | — |
Not a dietary nutrient — supplement / pharmaceutical only
- Amount
- N/A
- %DV
- —
Choosing a product
What to look for on the label — and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is lumbrokinase a blood thinner?⌄
Yes, it has fibrinolytic and anticoagulant activity. Avoid combining with prescription blood thinners without medical guidance.
How does lumbrokinase compare to nattokinase?⌄
Both are oral fibrinolytics from natural sources. Lumbrokinase is generally more potent per dose but with similar clinical considerations.
References by claim
Ischemic stroke recovery (adjunct to standard care)
Cardiovascular / thromboembolic disease (general)
Memorial Sloan Kettering Cancer Center — About Herbs — Lumbrokinase (search interface) (2024) link
Track Lumbrokinase with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.